Drawings

Figure 1: Changes in platelet levels for administration regime 1

(75 mg/m^2 of N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2-yl-carbonylamino]ethoxy}benzamide hydrochloride administered twice daily for 14 consecutive days followed by 7 days without treatment)




Figure 2: Changes in platelet levels for administration regime 2

(75 mg/m^2 of N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2-yl-carbonylamino]ethoxy}benzamide hydrochloride administered twice daily for 4 consecutive days followed by 3 days without treatment)

